There’s a new vaccine coming to the US which will save shots for infants, but it won’t be in use until next year.
A new-ish vaccine is coming to the US next year which will decrease the number of shots needed at 2, 4 and 6 months of age. It was actually approved for use in the US in 2018 but due to production and marketing reasons, it will not launch here until 2021. Also, because it is only licensed for use in the first 3 doses of these vaccines, it will have a limited impact on most babies.
Vaxelis, produced by the MCM Vaccine Company, will protect against Hepatitis B, Haemophilus influenza type B, polio, diphtheria, pertussis (whooping cough) and tetanus. It is licensed for use at 2, 4 and 6 months of age but NOT at 15 months, when many infants need boosters of several of these components. The net effect is that for pediatric practices using this new vaccine, babies will get 1 or 2 fewer injections compared to the previous routine. But since the use is only at 3 ages, the impact will be limited. Still good news, as less shots providing the same protection is always good!
An interesting tidbit here is that “MCM Vaccine Company” is a joint venture between Merck and Sanofi Pasteur, 2 giants in the vaccination field. This will be their first joint venture.